

## $\underset{\text{Atomization Portfolio}}{MAD^{\$}}$





## MAD Nasal

Intranasal Mucosal Atomization Device\*

#### The safe and painless way to deliver medications\*

- The soft, conical plug on the tip is designed to form a seal with the nostril, preventing expulsion of fluid
- The spray atomizes drugs into a fine mist of particles 30 100 microns in size

#### Rapid absorption<sup>1</sup>

 Atomized nasal medications allow rapid absorption across mucosal membranes into the bloodstream, avoiding first-pass metabolism<sup>2</sup>

#### **Patient comfort**

• Non-invasive and needle free

#### **Controlled administration**

- Simple delivery system appropriate for both ALS and BLS
- Atomizes in any position
- No sterile technique required



#### MAD Nasal<sup>™</sup> Intranasal Mucosal Atomization **Device Specifications**

Typical Particle Size	30 – 100 microns
System Dead Space	MAD100/MAD110/MAD130/MAD140 = 0.15 mL MAD1400S = 0.16 mL MAD300 = 0.06 mL
Tip Diameter	0.17 inches (4.3 mm)

\*For use with drugs approved for intranasal delivery

MAD Nasal <sup>™</sup> Intranasal Mucosal Atomization Device		
ITEM NUMBER	PRODUCT DESCRIPTION	QTY/BOX
MAD100	MAD Nasal <sup>™</sup> Device with 3 mL Syringe	25
MAD110	MAD Nasal <sup>™</sup> Device with 1 mL Syringe	25
MAD130	MAD Nasal <sup>™</sup> Device with 1 mL Syringe and Vial Adapter	25
MAD140	MAD Nasal <sup>™</sup> Device with 3 mL Syringe and Vial Adapter	25
MAD1400S	MAD Nasal <sup>™</sup> Device with 3 mL Oral Syringe and Vial Adapter	25
MAD300	MAD Nasal <sup>™</sup> Device without Syringe	25

## Using the MAD Nasal<sup>™</sup> Device





Pierce the Remove and discard medication vial the green vial adapter cap. vial adapter.

with the syringe in the device).



Using the free hand to hold the occiput of the head stable, place the tip of the MAD Nasal<sup>™</sup> Device snugly against the nostril aiming slightly up and outward (toward the top of the ear).

#### **Tips to Improve Success**

- 1. Minimize volume, maximize concentration
- Use the appropriately concentrated drug
- Follow drug manufacturer directions

See IFU for complete instructions

# the nostril.

- - Atomize the drug (rather than drip it in) to cover broad surface area
  - Use BOTH nostrils to double the absorptive surface area

Aspirate the proper volume of medication required to treat the patient (including medication to account for the dead space



Remove (twist off) the vial adapter from the syringe and discard it in a sharps container.



Attach the MAD Nasal<sup>™</sup> Device to the syringe via the luer lock connector.



Briskly compress the syringe plunger to deliver half of the medication into



Move the device over to the opposite nostril and, repeating steps 6 and 7, administer the remaining medication into the nostril if indicated.

#### 2. Maximize total mucosal absorptive surface area

· Aim slightly up and outwards to cover the turbinates and olfactory mucosa

#### **3. Beware of abnormal** mucosal characteristics

- Mucus, blood and vasoconstrictors may reduce absorption<sup>2</sup>
- Suction nostrils or consider alternate drug delivery method in these situations

1.866.246.6990 or cs@teleflex.com

### MADgic<sup>®</sup> Laryngo-Tracheal Mucosal Atomization Device\*

#### A versatile choice to administer medication\*

- Consistent, fine atomized spray for direct coverage of nose, pharynx, larynx and trachea
- Long, narrow stylet is designed to be gently curved and flexible, allowing it to reach a patient's vocal cords for targeted coverage
- Adapts to any luer-lock syringe
- Available in adult and pediatric sizes

#### Rapid absorption<sup>1</sup>

- Atomizes drugs into a fine mist
- Delivers particles at optimal size for rapid mucosal absorption<sup>1</sup>

#### Reduced cough

• In procedures where a cough upon emergence can cause adverse events, application of topical lidocaine on the laryngotracheal region has been shown to provide a smooth emergence from general anesthesia with reduced coughing<sup>3</sup>

#### **Patient comfort**

Adequate topical anesthesia has been shown to:

- Enhance patient comfort<sup>4</sup>
- Facilitate patient compliance<sup>4</sup>

## Using the MADgic<sup>®</sup> Device



Atomize topical anesthetic into nose/mouth/throat using the MADgic<sup>®</sup> Device.





See IFU for complete instructions



**MAD700** 

#### <sup>•</sup>MAD720

MADgic <sup>®</sup> Device Specifications			
Typical Particle Size	30 – 100 microns		
System dead space	0.13 mL MAD720 / 0.25 mL MAD600 / 0.19 mL MAD700		
Tip Diameter	0.18 inches (4.6 mm)		
Applicator Length	4.5 inches (11.4 cm) MAD720 / 8.5 inches (21.6 cm) MAD600 and MAD700		

#### MADgic<sup>®</sup> Laryngo-Tracheal Mucosal Atomization Device

TEM NUMBER	PRODUCT DESCRIPTION	QTY/BOX
MAD600	MADgic <sup>®</sup> Device with 3 mL Syringe	25
MAD700	MADgic® Device without 3 mL Syringe	25
MAD720	MADgic <sup>®</sup> Pediatric Device without 3 mL Syringe	25

\*For use with drugs approved for intranasal and oropharyngeal delivery

additional anesthetic into glottic area.



Position patient for intubation, atomize anesthetic onto vocal cords. Proceed to intubate as desired.



1.866.246.6990 or cs@teleflex.com

### MADomizer<sup>®</sup>

#### **Bottle Atomizer\***

#### A simple, effective delivery system for medications\*

- For use with topical anesthetics, vasoconstrictors, and other nasal or oral medications
- Consistent, fine atomized spray (approximately 30 100 microns)

#### Rapid absorption<sup>1</sup>

• Atomized particles dispersed across a broad area of the nasal mucosa are the ideal size for rapid absorption of medication

#### Reduced risk of cross-contamination

Unique pump design and disposable applicator tip reduces the risk of patient cross-contamination that can occur with conventional atomizers<sup>5</sup>

• Features a positive displacement pump with unidirectional flow





MAD510 Disposable Tip

MADomizer <sup>®</sup> Device Specifications		
Typical Particle Size	30 – 100 microns	
Spray Volume	0.1 mL / spray	
Tip Diameter	0.19 inches (4.82 mm)	
Applicator Length	4.75 inches (12.10 cm) end of tip to end of thumb landing / 2.25 inches (5.70 cm) end of tip to end of clip	
Bottle Volume	20 mL	

MADomizer <sup>®</sup> Bottle Atomizer Device Ordering				
ITEM NUMBER	PRODUCT DESCRIPTION	QTY/BOX		
MAD500	MADomizer® Bottle Atomizer Device	5		
MAD510	MADomizer® Disposable Tip	50		
MAD515	MADomizer® Pull Tab Cap	20		
MAD520	MADomizer <sup>®</sup> Replacement Bottle Clip	5		

## Using the MADomizer<sup>®</sup> Device





Place the disposable applicator (MAD510) tip in nostril or oropharyngeal cavity.



Clean the exterior surface of the bottle and pump. Refer to the Instructions for Use for additional information.

Place protectiv for storage.\*

See IFU for complete instructions



\*For use with drugs approved for intranasal and oropharyngeal delivery.



Compress the pump to spray solution into nostril or oropharyngeal cavity.



Place protective cap on pump stem



- Discard applicator (MAD510) after each patient use.
- \*Repeat steps 1–5 until all of the solution has been consumed or is no longer needed. The glass bottle and pump may not be reused. See Instructions for Use for single and multiple-patient component clarifications. Dispose of glass bottle and pump in accordance with federal, state and local regulations.

To place an order, please contact Teleflex Customer Service at: 1.866.246.6990 or cs@teleflex.com



Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, and urology. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow<sup>®</sup>, Deknatel<sup>®</sup>, LMA<sup>®</sup>, Pilling<sup>®</sup>, QuikClot<sup>®</sup>, Rüsch<sup>®</sup>, UroLift<sup>®</sup>, and Weck<sup>®</sup> – trusted brands united by a common sense of purpose.

#### **Corporate Office**

Phone +1 610 225 6800, 550 E. Swedesford Road, Suite 400, Wayne, PA 19087, USA

#### **Regional Offices**

United States: Phone +1 919 544 8000, Toll Free 866 246 6990, cs@teleflex.com, 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

Latin America: Phone +1 919 433 4999, la.cs@teleflex.com, 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

International: Phone +353 (0)9 06 46 08 00, orders.intl@teleflex.com, Teleflex Medical Europe Ltd., IDA Business and Technology Park, Dublin Road, Athlone, Co Westmeath, Ireland

Australia 1300 360 226 Austria +43 (0)1 402 47 72 Belgium +32 (0)2 333 24 60 Canada +1 (0)800 387 9699 China (Shanghai) +86 (0)21 6163 0965 China (Beijing) +86 (0)10 6418 5699 Czech Republic +420 (0)495 759 111 France +33 (0)5 62 18 79 40 Germany +49 (0)7151 406 0 Greece +30 210 67 77 717 India +91 (0)44 2836 5040 Italy ++39 0362 58911 Japan +81 (0)3 6632 3600 Korea +82 2 536 7550 Mexico +52 55 5002 3500 Netherlands +31 (0)88 00 215 00 New Zealand 0800 601 100 Portugal +351 22 541 90 85 Singapore (SEA non-direct sales countries) +65 6439 3000 Slovak Republic +421 (0)3377 254 28 South Africa +27 (0)11 807 4887 Spain +34 918 300 451 Switzerland +41 (0)31 818 40 90 United Kingdom +44 (0)1494 53 27 61

For more information, please visit teleflex.com.

References:

- 1. Suresh M. Management of Predicted Difficult Airway in A Parturient Undergoing Cesarean Delivery, where Airway Management is Necessary. *Shnider and Levinson's Anesthesia for Obstetrics*. 2013;(24):381-382.
- 2. Corrigan M, Wilson S, Hampton J. Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. American Journal of Health-System Pharmacy. 2015; 72(8): 1544-1554
- 3. Diachun CA, Tunink BP, Brock-Utne JG. Suppression of cough during emergence from general anesthesia: laryngotracheal lidocaine through a modified endotracheal tube. *Journal of Clinical Anesthesia*. 2001 13(6):447-451.
- 4. Leung Y, Vacanti FX. Awake without complaints: maximizing comfort during awake fiberoptic intubation. Journal of Clinical Anesthesia. 2015;27(6):517-519
- 5. Wolfe T, Hillman T, Bossart P. The Comparative Risks of Bacterial Contamination between a Venturi Atomizer and a Positive Displacement Atomizer. *American Journal of Rhinology & Allergy*.2002;16(4):181-186.

Rx only.

Teleflex, the Teleflex logo, MAD, MADgic, MAD Nasal, and MADomizer are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2022 Teleflex Incorporated. All rights reserved. MC-007486 (08/2022)

